Core Viewpoint - The successful IPO of Guangzhou Kelairedi Medical Equipment Co., Ltd. on the Beijing Stock Exchange marks a significant turnaround for the company after its previous failure on the ChiNext board, reflecting a new trend in the medical device industry where companies adjust their business structures and capital paths to reattempt listing [4][15]. Industry Overview - Kelairedi operates in the field of tumor radiation therapy auxiliary equipment, which is one of the three main treatment methods for tumors alongside surgery and chemotherapy. The increasing incidence of tumors and advancements in precision medicine are driving the growing application of radiation therapy [5][8]. - The positioning and fixation devices used in radiation therapy are critical for ensuring treatment accuracy, as patients require consistent positioning over multiple sessions [5][8]. Company Profile - Founded in 2001 and headquartered in Guangzhou, Kelairedi focuses on the research, production, and sales of positioning devices for radiation therapy and rehabilitation aids. The company ranks third globally in the positioning product market with a 7.0% market share and leads the domestic market with a 42.5% share [9][11]. - Kelairedi has accumulated multiple patents in low-temperature thermoplastic materials, positioning films, and shaping pads, and its products are sold both domestically and through overseas distributors [11]. Financial Performance - Kelairedi's revenue has remained stable, with approximately CNY 238 million (around USD 33 million) in 2023, showing a slight increase from CNY 233 million in 2022. However, the company's profit margins are relatively small, with a net profit of approximately CNY 3.1 million in 2023, down from CNY 6.77 million in 2022 [13][14]. - The company's total assets were about CNY 329 million, with net assets around CNY 163 million by the end of 2023, indicating it operates as a typical mid-sized medical device company with stable revenue but limited profit capacity [14]. IPO Pathway Analysis - Kelairedi's transition from the ChiNext board to the Beijing Stock Exchange highlights the suitability of the latter for mid-sized manufacturing enterprises, particularly those with revenues between CNY 200 million and CNY 500 million and smaller profit margins [17]. - The recognition of niche medical device companies has increased as the domestic medical device supply chain matures, allowing smaller firms to gain acceptance in the capital market [18]. - Kelairedi's current stable growth phase aligns well with the Beijing Stock Exchange's market positioning, suggesting that more mid-sized medical device companies may consider this exchange for their IPOs in the future [19].